John Parkinson

If the company gets approval it would be the first dispersible single tablet regimen containing dolutegravir.

A clinician provides an overview of the data on the microbiota-based live biotherapeutic, RBX2660, which in phase 3 studies has shown safety and reduction in recurrent C difficile infection (rCDI).

Investigators wanted to understand this phenomenon with a group of antiretroviral (ART) naïve people with HIV (PWH).

Investigators examined asymptomatic infection and the duration of viral shedding in symptomatic breakthrough infections in a phase 3 study with the AZD1222 COVID-19 vaccine.

This type of stewardship is a means of reducing unnecessary testing, getting the appropriate diagnosis more efficiently, and getting patients the appropriate therapy in a timely manner.

In a study looking at one urban South Florida hospital, the pandemic negatively impacted testing.

A study’s findings support the use of the therapy earlier in the course of COVID-19 in hospitalized patients.

During the pandemic, hospitalists prescribing patterns changed, reflecting new data, clinical experience, and the introduction of new therapies.

The Infectious Diseases Society of America’s (IDSA) 2017 guideline saw an increase in using vancomycin as a first line therapy for Clostridioides difficile (CDI).

A team from a tertiary center in the Middle East used a multidisciplinary approach to increase immunization.

Ferring is presenting data from five studies at this week’s IDWeek about its investigational biotherapeutic, RBX2660, being studied for this problematic bacterium.

The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.

The emergence of this fungal infection remains mysterious as the world experiences more outbreaks.

In a departure from the independent APIC advisors, CDC Director Rochelle Walensky, MD, has decided to recommend boosters for people in high-risk occupations.

The Advisory Committee on Immunization Practices posed a series of 4 questions related to a potential third shot of the Pfizer-BioNTech COVID-19 vaccine in various populations.

The federal agency will grant an Emergency Use Authorization (EUA) for the third dose for seniors, those deemed high risk, and those with jobs that put them at risk of infection.

With fecal microbiota transplants (FMT) becoming a potential emerging therapy for these patients, here are some aspects to consider when treating.

With the Delta cases surging in recent weeks, and the upcoming flu season almost upon us, here is a glimpse of what providers and the public can expect when both viruses are circulating.

A smaller dosage was used and with their results the two companies plan to submit their data to governmental regulatory agencies around the world.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.

The VRBPAC voted 16-2 on Friday afternoon on the question they were presented.

A Food and Drug Administration (FDA) committee will discuss this topic as it pertains to the potential approval of a third dose of the Pfizer-BioNTech COVID-19 vaccine. The results of this meeting could have ramifications for the Biden Administration’s COVID-19 health policy.

Based on recent studies, the company sees benefits in administering booster doses.

Recent data shows that all three COVID-19 vaccines being administered in the United States are showing high rates of vaccine effectiveness (VE).

Higher HIV viral loads and additional heart disease factors increase the risk as well.

Johnson & Johnson’s vaccine regimen induced neutralizing antibody responses in 98% of participants 21 days after the second dose.

In a recent speech, Pfizer’s CFO says it might be a matter of weeks for submitting an application for children 6 months to 5 years old.

A study from Mexico shows that maternal mortality increased nearly 60 percent during the COVID-19 pandemic, and reaffirms the importance of both COVID-19 and influenza vaccinations for pregnant women.

This decision is in spite of the government’s vaccine group saying that vaccines only marginally benefit this age group.